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Varicose veins are the most common vascular disease 
and it is due to incompetent valves, presenting with 
heaviness, aching and cramps of lower limbs.1 It is 
defined as dilated, usually tortuous, subcutaneous 
veins ≥ 3mm in diameter measured in the upright 
position with demonstrable reflux.2 
 
Its overall prevalence is 20% to 60% (25-30% among 
women and 15% in men). It has a genetic predisposition 
as when both parents are affected, there is a 90% 
chance for the offspring to get the disease and when 
one parent is affected, chances of inheritance in 
daughter is 60% and the chance of inheritance in son is 
25%.3 The prevalence of varicose vein depends on the 
following factors : gender, age(most commonly in the 
age group of 55 –64 years,  and least in the age group of  
18 –24 years), based on ethnicity, more prevalent 
among North America and Europe; least among South 
America and  India.4 Other factors influencing 
prevalence are pregnancy, occupation and lifestyle 
(smokers, constipation, prolonged standing increases 
the risk).2 In a study among 100 teachers in 
Trivandrum, prevalence of varicose vein was 19%. In a 
study among sweepers (men) it was 25.08% and 6.8% 
(South & North India).5 About 20-25 million Americans 
have varicose veins.6 
Treatment of varicose vein includes: conservative: 
compression stockings, intermittent pneumatic 
compression. Active:  
 
1. Surgical: TSSA(Trendelenberg  stripping and stab 
avulsion), SPJ (Sapheno Popliteal Junction)Ligation, 
ambulatory phlebectomy, cryosurgery. 
2. Non-surgical : Sclerotherapy (reticular veins), 
endovenous thermal ablation. 
In foam sclerotherapy which was introduced in 2001, 
lipid membranes(endothelial cells) are destroyed by 
sclerosant(detergent), by inducing sclerosis.  
 
Tessari’s Method: Here, sites are marked, and two 
syringes are connected by a three-way tap. 1:3 or 1:4 -
sclerosant: air is drawn into syringe and then oscillated. 
The foam is stable only for 2 minutes. The veins are 
emptied and foam is injected (1-2 ml, maximum 10-20 
ml) from superficial veins to Long Saphenous Vein or 
Short Saphenous Vein. Incidence of complications is 
directly proportional to the volume of sclerosant 
injected. Compression bandage is applied and left in-
situ for 7-10 days.2 
      
Sclerosant approved by US FDA are 1. Sodium 
morrhuate and Sodium tetradecyl Sulfate. In UK, 
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INTRODUCTION: Foam sclerotherapy is used for treating varicose veins in our institution for patients who are not willing for surgery, 
debilitated patients, recurrent ulcers, cosmetic & in SFV (Sapheno Femoral Vein) <6 mm size.  
AIM: The aim of this study was to find and assess the rate and pattern of post–sclerotherapy complications in our institution compared 
with international standards.  
MATERIALS AND  METHOD: The present study was  retrospective in nature and case records of patients who underwent foam 
sclerotherapy [2009-2013, lower limb-Ultrasound (USG) guided and blind] in our hospital [10% Sodiumtetradecylsulfate (STS), Tessari 
technique] were assessed to look for indication, tolerance to the procedure and immediate outcomes. A  pre-tested and pre-validated 
questionnaire was used and physical examination were done to assess post-procedural complications. Statistical significance was p< 0.05.  
RESULTS: Among 112 patients, 62.5 % were aged >50 years and 69% were males. It was observed that 22% had indication as  recurrence;  
43% had mild pain during procedure and 36.6% developed post-foam sclerotherapy complications. 47.6% of patients whose age were <50 
years had CEAP(Clinical Etiological Anatomical Pathological) criteria C2(p=0.007). 48.8% with complications had multiple criteria(p=0.012) 
and 57.7% C2 had least complication (p=0.000). Cosmetic indication showed least tolerance. Use of 10% STS was found to have lesser 
complication rate (36%), compared to study which had 76% success with STS 3%  and complication-64%.  
CONCLUSION: Foam sclerotherapy is less invasive and its efficacy could be improved by performing under USG guidance, selection of 
sclerosant, appropriate candidate (age>50 years, multiple CEAP criteria, without pre-existing co-morbidities).  
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polidocanol is also used.7 The sclerosant used in our 
hospital is 10% Sodium tetradecyl sulphate.  
 
The complication rate of foam sclerotherapy is <1%, 
which commonly includes phlebitis, pigmentation, 
headache, superficial skin necrosis, visual 
disturbances, chest tightness.1,2 
 
Sclerotherapy, even if less invasive, is not widely used. 
In our hospital, sclerotherapy is carried out in patients 
who are not willing for surgery, debilitating patients, 
recurrent ulcers, cosmetic purposes and in patients 
with <6 mm SFV size. The aim was to find out and 
assess the rate and pattern of post–sclerotherapy 
complications. The study also intended to analyse the 
complication rate of the procedure in US and UK and 
to find out whether the present methods are to be 
modified for better results. 
 
MATERIALS AND METHOD 
Ethical Consideration: This study was approved by 
Dr.SMCSI Medical College and Hospital ethical 
committee. 
 
Method: The study group comprised of 112 patients 
who had undergone foam sclerotherapy (both 
ultrasound guided and blind sclerotherapy) during the 
years 2009-2013. Patients who were willing, had 
recurrent venous ulcers, debilitating, GSV size < 6mm, 
who had undergone foam sclerotherapy during 2009-
2013 were included in the study. Those who had 
incomplete case records were excluded from the study. 
The study included dependent variables like superficial 
skin pigmentation at site of injection, pain at site of 
injection, skin necrosis, transient blindness and 
transient renal failure. Independent variables included 
name, age, sex, residence, morbidity. 
 
Case records were studied for indications of 
sclerotherapy, details of the procedure, tolerance to the 
procedure and immediate outcomes. Data regarding 
post procedure followed upto 3 months and 6 months 
were obtained from case records. The data was entered 
in MS Excel and analysed using software (SPSS, version 
22.0). Complication rate was computed as the total 
number of complications divided by the total subjects 
who had undergone foam sclerotherapy. Pattern of 






Among 112 subjects, 77 were males and 35 were females. 
37.5% belonged to the age group of 31-50 years, 37.5% 
were aged 51-70 years. 22% of the subjects underwent 
foam sclerotherapy due to recurrence either after 
surgery (mostly as thread veins) or previous foam 
sclerotherapy. 16% got it done for cosmetic benefits. 
Among the total subjects surveyed, only 81% had their 
data regarding tolerance to procedure being recorded. 
Among them, 43% experienced mild pain yet tolerable, 
while 20% had no pain and 5 % had severe pain during 
the procedure. 97.32% of foam sclerotherapy were done 
under ultrasound guidance. Among the study subjects, 
36.61% was found to have post-foam sclerotherapy 
complications, immediately after the procedure/within 
3-6 months of procedure. 
 
 The most common complication was skin 
pigmentation (19%) which lasted for more than 1 week 
after the procedure and for which patient had to revisit 
the general surgery OPD. Next common complication 
found was ulcer at the injection site, majority of whom 
had associated pain at the injection site. Next common 
complication was skin necrosis which took long time to 
settle. These complications needed hospitalisation. 
Other less common complications observed were Deep 
Vein Thrombosis (DVT)(2%) and itching. Among 
these, itching associated with skin 
pigmentation/ulcer/necrosis had been excluded and 
included only those who presented with itching alone 
as the complaint which accounted for about 1 %. 
Recurrence after foam sclerotherapy was one of the 
main complications which led to repetition of foam 
sclerotherapy after first course. Renal failure was not 
found in any of the patients. 
 
Among the subjects who had undergone foam 
sclerotherapy, 57% were in the age group <50 years  and 
47.6% of them  had CEAP  (Clinical-Etiological-
Anatomical-Pathophysiological) criteria C2, next being 
more common than one criteria(C1-C6)(p=0.007). 
Those belonging to age >50 years, 47.9% had more than 
one CEAP criteria (p=0.007) and 37.5% had C2 criteria. 
41.5% of subjects aged<50 years had ulcer as indication 
for foam sclerotherapy(p=0.015). 27.1% of subjects 
aged>50years presented with recurrence of varicose 
vein of lower limb as indication for foam sclerotherapy. 
Interestingly 25% of older age group presented in OPD 
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whereas it was only 9.4% among younger age group 
(p=0.026). Better tolerance to procedure was shown by 
those with age<50 years (14.1 %). 35.9% with age<50 
years and 37.5% with age>50 years had post foam 
sclerotherapy complications atleast within 6 months of 
procedure (p=0.827). Both the age groups had skin 
pigmentation as the most seen complication (18.8 %) 
with a p value=0.978. 
 
Among subjects who had post foam sclerotherapy 
complications,   56.1 %     belonged    to    age  <50 years  
 
(p=0.865). 48.8% of those with complications belonged 
to multiple CEAP criteria (p=0.012) and those with C2 
criteria were found to have least complications 
(p=0.000, table 1). 41.5% of subjects who had 
complications was found to have ulcer as their 
indication for foam sclerotherapy and the relation was 
found to be statistically significant (p=0.000, table 1). 
Next common indication was recurrent varicose 
vein(39%) and skin changes(31.7%), with a statistically 
significant relation to occurrence of complication (p 









CHI SQUARE (p 
VALUE) 
 n % n %  
1. Age 
< 50 years 23 56.1 41 57.7 0.029(p=0.865) 
>50 years 18 43.9 30 42.3 
2. CEAP criteria  
C1 1 2.4 0 0 2.025(p=0.155) 
C2 7 17.5 41 57.7 16.886(p=0.000) 
C3 4 9.8 7 9.9 0.000(p=0.986) 
C4 0 0 1 1.4 0.917(p=0.338) 
C5 1 2.4 0 0 2.025(p=0.155) 
C6 7 17.1 4 5.6 3.677(p=0.051) 
Subjects having 












3. Indication for foam sclerotherapy 
A). Cosmetic 8 19.5 10 14.1 0.568(p=0.451) 
B). Skin changes 13 31.7 4 5.6 13.724(p=0.000) 
C). Edema 7 17.1 9 12.7 0.410(p=0.522) 
D). Ulcer 17 41.5 8 11.3 13.668(p=0.000) 
E). Minor 
abrasion 
1 2.4 11 15.5 5.644(p=0.018) 
F). Recurrence 16 39 8 11.3 11.893(p=0.001) 
4. Mode of foam sclerotherapy 
A). USG guided 39 95.1 70 98.6 1.145(p=0.285) 
B). Blind 2 4.9 1 1.4 1.145(p=0.285) 
5. Level of tolerance 
a). No pain 2 4.9 2 2.8 0.309(p=0.578) 
b). Mild pain 10 24.4 3 4.2 10.012(p=0.002) 
c). Severe pain 5 7 0 0 4.692(p=0.030) 
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TOLERANCE TO 
PROCEDURE 
YES NO CHI SQUARE (p VALUE) 
 n % n %  
1. Age 
<50 years 1 1.6 63 58.3 1.767(p=0.184) 
>50 years 3 75 45 41.7 
2. CEAP criteria 
2. CEAP multiple 
criteria present 
3 75 1 25 2.928(p=0.087) 
3. Indication for foam sclerotherapy 
a)cosmetic 0 0 18 16.7 1.420(p=0.232) 
b)skin changes 1 25 16 14.8 0.271(p=0.603) 
c)edema 2 50 14 13 3.014(p=0.083) 
d)ulcer 2 50 23 21.3 1.530(p=0.216) 
e)minor abrasion 0 0 12 11.1 0.924(p=0.336) 
f)recurrence 0 0 24 22.2 1.969(p=0.161) 
4. Complication present 
4.complication 
present 
2 50 39 36.1 0.309(p=0.578) 
5. Post foam sclerotherapy complication 
A). Skin necrosis 0 0 11 10.2 1.596(p=0.450) 
B). Skin pigmentation 1 25 20 18.5 0.311(p=0.856) 
c). DVT 0 0 2 1.9 0.514(p=0.773) 
D). Itching 2 50 5 4.6 7.916(p=0.019) 
E). Headache 0 0 1 .9 0.411(p=0.814) 
F). Ulcer 1 25 12 11.1 0.613(p=0.736) 
G). Renal failure 0 0 0 0 0 





minor abrasion as the indication for foam 
sclerotherapy were found to have least (15.5%) 
occurrence of complications (p=0.018) (Table 1). 
 
It was observed that 60.5% of subjects having multiple 
CEAP criteria belonged to age>50years.  Among 
subjects who presented with multiple CEAP criteria, 
47.4% presented with ulcer, 31.6% with edema as their 
indication for foam sclerotherapy. 17.6% of those with 
single CEAP criteria had cosmetic indication. 97.4% of 
subjects with multiple CEAP criteria had undergone 
with USG guided foam sclerotherapy. Post foam 
sclerotherapy complications were present in 52.6% of 
subjects having multiple CEAP criteria- p value of 0.012. 
Statistically significant relation was found among 
presence of multiple CEAP criteria and occurrence of 
all post-foam sclerotherapy complications were 
studied. 
 
Majority (75%) of subjects of older age group 
(>50years) and having multiple CEAP criteria were 
found to tolerate the procedure better than those of 
younger age group(p=0.184 & p= 0.087 respectively). It 
has been found that none of those having cosmetic 
indication for foam sclerotherapy could tolerate the 
procedure (p=0.232). 50% of subjects who could not 
tolerate the procedure were later found to have post-
foam sclerotherapy complications (p=0.578). Subjects 
with post-foam sclerotherapy complications like skin 
necrosis (p=0.450), DVT (p=0.773), headache (p=0.814) 
have not been found to tolerate the procedure (table 2).   
 
DISCUSSION 
There are various treatment choices for lower limb 
varicose veins. Foam sclerotherapy causes complete 
endothelial damage and eventually fibrosis of the 
entire vein wall without recanalization and locates the 
points of irregular flow in the veins permanently 
obliterated by the sclerosant injection.4 In our 
institution 10% sodium tetradecyl sulphate is used, a 
detergent sclerosant agent. With this, the valves that 
are permanently damaged can regain their normal 
functions. The most important aspect of the treatment 
is to minimize the local venous hypertension by 





 International Healthcare Research Journal 2021;4(10):OR7-OR14  
Complications, Indication & Tolerance of Foam Sclerotherapy                                                                                        Oli PT et al.  
interrupting the points of leakage into the superficial 
network by the perforating veins. The migration of 
sclerosing solution into isolated segments of the 
injected superficial vein (digital compression) will 
effectively close the perforator complex of perforators. 
The incompetent perforators are located almost always 
near changes in the skin and in typical locations in the 
legs.8  
 
Among the 145 subjects selected for the study during 
the year 2009-2013 in our hospital, according to 
inclusion criteria and availability of proper data 
records, 112 were actually included in the study, 77 were 
males and 35 were females. Of this, 94.64% belonged to 
age<70 years, 57% were aged <50 years, 19.64% aged 
<30 years. 
 
22% of the subjects underwent foam sclerotherapy due 
to recurrence either after surgery (mostly as thread 
veins) or previous foam sclerotherapy or due to 
ulceration. 16% got it done for cosmetic benefits, 15% 
due to skin changes,14% edema and 11% minor 
abrasions, in contrast to an Italian study by Tessari L et 
al. wherein 70% of the sclerotherapy sessions were 
performed on recurrent varices, or collaterals and 30% 
for reticular varices and telangiectases.9  
 
In another study, common indications found were (a) 
pain in the affected limb - 38 patients (76%); (b) 
eczema - 40 patients (80%); (c) oedema - 15 patients 
(30%); (d) ulceration - 15 patients (30%); (e) 
lipodermatosclerosis - 10 cases (20%); and (f) 
telangiectasia and atrophie blanche - 2 cases (4%), 
which reveals a similar group of indications but lesser 
prevalence in present study. The disparity may be 
because the above mentioned research done by 
Subbarao.et.al was based on dermatological outcome 
of the treatment and thus skin changes were more 
included as the indications.10 
 
A  research carried out  by Fun SK on the etiology and 
symptomatology of varicose veins of lower limbs 
showed that patients having pain were 59%, 
pigmentation was seen in 58%, edema in 53%, eczema 
in 29%, ulceration in 28%, bleeding in 21% and 
lipodermatosclerosis in 20% which correlates well with 
the current study in case of prevalence of ulcer as 
indication(22%).11 
 
 Among the total subjects studied, only 81% had their 
data regarding tolerance to procedure being recorded.  
 
Among them, 43% experienced mild yet tolerable pain, 
which was found to be a factor that increases the 
patient compliance to procedure and makes them 
willing for repeated sittings. 
 
97.32% cases were done under ultrasound guidance 
which improved the efficacy of the procedure by 
effectively localising the incompetence. 
 
Among the study subjects, 36.61% were found to have 
post-foam sclerotherapy complications, immediately 
after the procedure/within 3-6 months of procedure, 
which goes in hand with the findings in study 
conducted by Subbarao.et.al, in which 64% had post-
foam sclerotherapy complications like bruising-38%, 
pigmentation-10%, recurrence-4% ,DVT-2%.10 This 
study showed a higher incidence of complications 
possibly due to inclusion of thrombophlebitis, which is 
considered as a part of mode of action of sclerosant and 
not taken into account in the present study. 
 
Post-sclerotherapy complications observed in the 
present study were 10% skin necrosis, 19% skin 
pigmentation, 2% DVT, 1% itching, ulcer 12%, 
recurrence 7%  & no renal failure. Whereas the above 
study had not reported any case of skin necrosis.10 
Mostly observed post procedural complication was 
skin pigmentation (19%) which lasted for more than 1 
week after the procedure and for which patient had to 
revisit the general surgery outpatient 
department(OPD) and had undergone either repeat 
foam sclerotherapy or other treatment. Next most 
common complication found was ulcer at the injection 
site, majority of which had associated pain at the 
injection site. Next common was skin necrosis which 
required longest time period for recovery among the 
complications. These were the complications which 
had required hospitalisation. Other less common 
complications observed were DVT & itching. Among 
this, itching associated with skin 
pigmentation/ulcer/necrosis had been excluded. 
Recurrence after foam sclerotherapy was one of the 
main complications which led to repetition of foam 
sclerotherapy after first course, among which some 
even had to undergo surgical avulsion of the vein due 
to initial sclerotherapy failure. Another complication 
which had been looked for was renal failure which had 
not been reported in any of the patients may be due to 
plenty of oral fluids after the procedure. Other possible 
causes for the above mentioned complications were 
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thorough physical examination and radiographic 
studies before attributing to foam sclerotherapy. 
 
 Among the subjects who underwent foam 
sclerotherapy, those belonging to age <50 years 
presented with tortuous asymptomatic lower limb 
veins (C2) and also with more than one criteria (C1-C6) 
(p=0.007), showing complicated presentation. Such 
patients with multiple CEAP criteria showed 
statistically significant relation with more incidences of 
post sclerotherapy complications also. Younger age 
group presented more with ulcer as indication for the 
procedure whereas for older group it was recurrence 
which was probably due to time lapse after first 
occurrence of varicose vein. Interestingly 25% of older 
age group presented in OPD for cosmetic indication 
whereas it was only 9.4% among younger age group 
(p=0.026), yet they tolerated the procedure well. 
 
Among subjects who had post foam sclerotherapy 
complications, 56.1 % belonged to age<50 years 
(p=0.865). 
 
41.5% of subjects who had complications were found to 
have ulcer as their indication for foam sclerotherapy 
and the relation was found to be statistically significant 
(p=0.000). Next common indication was recurrent 
varicose vein (39%) and skin changes (31.7%), with a 
statistically significant relation to occurrence of 
complication with a p value of 0.001 and p=0.000 
respectively. Those with minor abrasion as the 
indication for foam sclerotherapy were found to have 
least (15.5 %) occurrence of complications (p=0.018). 
Among subjects who presented with multiple CEAP 
criteria, 47.4% presented with ulcer (p=0.000), 31.6% 
with edema(p=0.000) and 26.3% with skin 
changes(p=0.019) as their indication for foam 
sclerotherapy. 
     
17.6% of those with single CEAP criteria had cosmetic 
indication (p=0.547) for foam sclerotherapy.  97.4% of 
subjects with multiple CEAP criteria underwent a USG 
guided foam sclerotherapy (p=0.982). 
 
18.4% of subjects with multiple criteria had mild pain 
during the procedure. Post foam sclerotherapy 
complications were found to be present in 52.6% of 
subjects having multiple CEAP criteria and the relation 
was found to be statistically significant with a p value 
of 0.012. 
 
Statistically significant relation were found among 
presence of multiple CEAP criteria and occurrence of 
all post-foam sclerotherapy complications studied for : 
skin necrosis-18.4% (p=0.022), skin pigmentation-
31.6% (p=0.021), DVT-2.6% (p=0.043), itching-10.5% 
(p=0.039), headache-2.6% (p=0.021), ulcer-
15.8%(p=0.042), recurrence-10.5%(p=0.043). 
            
Majority (75%) of subjects in older age group (>50 
years) & having multiple CEAP criteria were found to 
tolerate the procedure better than those in younger age 
group (p=0.184 & p= 0.087 respectively). It has been 
found that none of those having cosmetic indication for 
foam sclerotherapy could tolerate the procedure 
(p=0.232). Those with recurrence of varicose vein in 
lower limb as the indication were also not found to 
tolerate the procedure (p=0.161). 
 
Among the 81% of procedure tolerance data available, 
50% of subjects who could not tolerate the procedure 
were later found to have post-foam sclerotherapy 
complications (p=0.578). Subjects who did not tolerate 
the procedure presented with post-foam sclerotherapy 
complications like skin necrosis (p=0.450), DVT 
(p=0.773), headache (p=0.814). 
 
In short, regarding tolerance to procedure, older 
individuals and those with multiple criteria were found 
to show better tolerance than those having cosmetic 
indication and recurrence of varicose vein. Better 
tolerance may be because multiple criteria varicose 
veins were all ultrasound guided procedures, reducing 
local reactions thereby. Also poor tolerance had ended 
up in post procedure complications also.  
 
Even if there are associated post procedural 
complications, sclerotherapy is found to be a safer and 
more compliant procedure which could manage many 
varicose cases on an OPD basis, as proved in a study by 
Kanter and Thibault, who in 1996 reported a 76% 
success rate at 24 months in treating saphenofemoral 
junction and great saphenous vein incompetence with 
STS 3% solution.12 In order to control reflux in the small 
saphenous vein, Padbury et al. found that ultrasound 
guided sclerotherapy was successful.13 Barrett et al. 
found that microfoam ultrasound guided sclerotherapy 
was effective in treating all sizes of varicose veins with 
high patient satisfaction and improvement in quality of 
life.14 
 
According to Cochrane Collaboration review of the 
medical literature "the evidence supports the current 
place of sclerotherapy in modern clinical practice, 
which is usually limited to treatment of recurrent 
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second Cochrane Collaboration review comparing 
surgery to sclerotherapy found out that sclerotherapy 
was better than surgery in terms of treatment success, 
complication rate and cost at one year, but surgery was 
better after five years.16  
 
The European Consensus Meeting on Foam 
Sclerotherapy in 2003 concluded that "Foam 
sclerotherapy allows a skilled practitioner to treat 
larger veins including saphenous trunks".17 
 
When so much evidence is given on the clinical success 
of a procedure which had been evolving over a decade 
to the present state, more research could aid to 
overcome present complications too, making it a better 
resort to varicose vein management. 
 
CONCLUSION 
On the grounds of available knowledge on benefits of 
foam sclerotherapy, despite of the presence of post-
procedure complications, it must be increasingly 
advocated to patients in indicated cases. Efficacy could 
be enhanced by performing under ultrasound 
guidance, selection of appropriate sclerosant, 
appropriate candidate. In the current study 
appropriate candidates were found to be older people 
with multiple CEAP criteria, without systemic illnesses 
who may predispose to complications studied 
herewith. 
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